Overview

Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study

Status:
Not yet recruiting

Trial end date:
2025-08-27

Target enrollment:

Participant gender:

Summary

This early phase I trial investigates how well duvelisib exposure before CAR-T cell manufacturing works to enhance immune profiles of T cells in patients with diffuse large B-cell lymphoma that has come back (recurrent) or does not respond to treatment (refractory). Duvelisib, an oral phosphoinositide 3-kinase (PI3K) inhibitor, may favorably change a patient's T cells to make them more efficient and have a longer duration for manufacturing of CAR-T cells.

Phase:

Early Phase 1

Details

Lead Sponsor:

Emory University

Collaborators:

National Cancer Institute (NCI)
Novartis
Secura Bio
Secura Bio, Inc.